

ATTORNEY DOCKET NO.: TNX99-05-01

Application No.: 09/991,470

Customer No.: 26839

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-16 (Canceled)

17. (Currently Amended) A method for inhibiting the binding of IgE to its high-affinity IgE receptor *in vivo* comprising administering to a patient in need thereof a composition comprising an adenoviral vector comprising a nucleic acid encoding an anti-IgE antibody or IgE binding fragment thereof.
18. (Canceled)
19. (Currently Amended) The method of claim 17 ~~[[18]]~~, wherein the anti-IgE antibody is Hu901.
20. (Canceled)
21. (Currently Amended) The method of claim 24 ~~[[20]]~~, wherein nucleic acid encodes an scFv of Hu901.
22. (Currently Amended) A method of suppressing or attenuating an IgE-mediated allergic disease *in vivo* comprising administering to a patient in need thereof a composition comprising ~~[[a]]~~ an adenoviral vector comprising a nucleic acid encoding an anti-IgE antibody or IgE-binding fragment thereof, wherein said anti-IgE antibody inhibits or blocks the binding of IgE to the high affinity IgE receptor.
23. (Currently Amended) The method of any one of claims 17, 19, 21 or 22, wherein ~~the vector is an adenoviral vector with~~ comprises a human cytomegalo virus promoter for expression of the anti-IgE antibody.

ATTORNEY DOCKET NO.: TNX99-05-01

Application No.: 09/991,470

Customer No.: 26839

24. (NEW) The method of claim 17, wherein the adenoviral vector encodes a single-chain Fv.
25. (NEW) A method of producing an anti-IgE antibody *in vivo* comprising administering to a patient in need thereof a composition comprising an adenoviral vector comprising a nucleic acid encoding an anti-IgE antibody or IgE binding fragment thereof.
26. (NEW) The method of claim 25, wherein the anti-IgE antibody is TES-C21.
27. (NEW) The method of claim 26, wherein the TES-C21 antibody has been humanized.